Unmet Needs in EGFR-Mutant Non-Small Cell Lung Cancer

This Phase 2 clinical trial (NCT07518160) targets patients with EGFR-mutant non-small cell lung cancer (NSCLC) whose disease has progressed after treatment with existing EGFR-TKIs. With the increasing number of patients developing resistance to Osimertinib (Tagrisso), the current standard third-generation treatment, there is an urgent need for alternative therapies. Shanghai Junshi Biosciences (688185.SH) aims to overcome these limitations through the combination of its two key pipeline assets. This combination offers a novel targeted therapy option for patients with resistance, who currently have limited treatment choices beyond conventional chemotherapy.

Synergistic Mechanism of Bispecific ADC and Targeted Inhibitor

The combination therapy, JS212, is a bispecific antibody-drug conjugate (ADC) that simultaneously targets EGFR and HER3, and is loaded with the topoisomerase I inhibitor Exatecan. JS111 (AP-L1898), which is co-administered, is a small molecule compound that inhibits EGFR exon 20 insertion and rare mutations. The principle is to simultaneously block tumor cell receptors with JS212 and deliver the drug, while JS111 completely blocks downstream signaling. This multi-pronged approach aims to overcome the resistance limitations of single agents by targeting multiple points in the biological pathway, representing a sophisticated R&D strategy.

Clinical Trial Design to Validate Safety and Efficacy

This trial is a multi-center, open-label study consisting of dose escalation and dose expansion phases. In the initial dose escalation phase, approximately 15 patients will be enrolled to determine the optimal dose using a Bayesian Optimal Interval (BOIN) model. JS212 will be escalated from 4.2 mg/kg to a maximum of 4.6 mg/kg every 3 weeks (Q3W), and JS111 will be administered orally once daily (QD) at a fixed dose of 160 mg. The initial safety and pharmacokinetic (PK) data obtained from this small patient cohort will undoubtedly guide the design of the subsequent Phase 3 trial.

Financial Background of Partnerships and Licensing Agreements

JS111, used in the combination therapy, was licensed by Junshi Biosciences from Wigen Biomedicine in 2020 for an upfront payment of 36 million yuan (approximately $5.3 million). Additional milestone payments of up to 436 million yuan (approximately $64 million) are payable based on development progress, along with a 50% royalty on net sales. In contrast, JS212, the bispecific ADC, was independently developed by Junshi, which received clinical trial (IND) approval from China's NMPA and the US FDA in 2025. The success of this combination therapy will demonstrate the synergy between its proprietary pipeline and licensed assets, creating an opportunity to further enhance the company's value.

Competitive Landscape in a Market Exceeding $10 Billion

The global market for EGFR-mutant NSCLC is estimated at approximately $8 billion to $16 billion in 2025 and is projected to reach $39 billion in 2036. Currently, the market for Osimertinib-resistant patients is dominated by Amivantamab (Johnson & Johnson) and Patritumab Deruxtecan (Daiichi Sankyo). If Junshi Biosciences can demonstrate differentiated safety and efficacy in this trial, it will be recognized for its independent R&D capabilities. In the long term, this could lead to global licensing deals with major multinational pharmaceutical companies, potentially becoming a significant source of revenue.